An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis

• Status: Completed
• Trial end date: 2009-04-15
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Tanezumab

Criteria

Inclusion Criteria:

• Male and female adults at least 18 years of age;

• Moderate to severe interstitial cystitis, with a mean pain intensity score above a pre-defined level.

Exclusion Criteria:

• Less than 6 months since onset of interstitial cystitis symptoms;

• History of recurrent urinary tract infections, or genitourinary cancer;

• History of hepatitis B, C or human immunodeficiency virus (HIV);

• Use of certain drugs given into the bladder up to 1 month prior to study entry.